Jackson Creek Investment Advisors LLC Reduces Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Jackson Creek Investment Advisors LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 690 shares of the company’s stock after selling 65 shares during the quarter. Jackson Creek Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $625,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Tidemark LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth about $29,000. Core Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $32,000. Frank Rimerman Advisors LLC bought a new position in Eli Lilly and Company during the 4th quarter valued at approximately $37,000. Finally, St. Johns Investment Management Company LLC raised its stake in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after buying an additional 37 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, August 19th. Bank of America increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Argus upped their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Finally, Truist Financial reissued a “buy” rating and set a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $961.76.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 876,900 shares of company stock worth $788,605,032 in the last three months. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.4 %

LLY stock opened at $956.53 on Wednesday. The business’s 50-day moving average is $895.06 and its two-hundred day moving average is $825.20. The company has a market cap of $909.09 billion, a price-to-earnings ratio of 140.87, a P/E/G ratio of 2.91 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts forecast that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.